McLaughlin Asset Management Inc. Invests $4.72 Million in Eli Lilly and Company $LLY

McLaughlin Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, Holdings Channel reports. The fund acquired 4,391 shares of the company’s stock, valued at approximately $4,719,000. Eli Lilly and Company makes up approximately 4.2% of McLaughlin Asset Management Inc.’s holdings, making the stock its 3rd largest position.

A number of other hedge funds also recently modified their holdings of the business. Wick Capital Partners LLC lifted its position in shares of Eli Lilly and Company by 169.6% in the fourth quarter. Wick Capital Partners LLC now owns 1,259 shares of the company’s stock worth $1,353,000 after purchasing an additional 792 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $38,000. Hamilton Wealth LLC grew its holdings in shares of Eli Lilly and Company by 57.4% during the 4th quarter. Hamilton Wealth LLC now owns 1,122 shares of the company’s stock valued at $1,206,000 after acquiring an additional 409 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Eli Lilly and Company by 0.6% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,100,864 shares of the company’s stock valued at $1,183,077,000 after acquiring an additional 6,168 shares in the last quarter. Finally, WealthPoint Financial LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth $208,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several articles highlighted Eli Lilly’s strong growth profile and ongoing investor support, including coverage that Ray Dalio’s Bridgewater sees LLY as a top growth name and that some analysts view the stock as undervalued on its growth narrative. Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio
• Positive Sentiment: Lilly’s pipeline news was broadly constructive, including completion of a retatrutide trial and early signs from its AJX-101 study, which suggest continued momentum in diabetes, obesity, and immunology programs. Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio
• Positive Sentiment: The company also expanded its AI drug-discovery ecosystem, with Charles River, Chai Discovery, and Axcelead DDP joining Lilly TuneLab, supporting longer-term innovation and partnership potential. Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
• Neutral Sentiment: Recent articles also noted Lilly remains a major leader in obesity treatment, with investor debate around whether newer competitors like Pfizer can take share; this underscores the size of the opportunity but also the competitive backdrop. Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
• Negative Sentiment: One of the bigger drags on sentiment was Lilly’s decision to halve a planned €2.7 billion Germany investment, citing European drug-pricing reforms that could pressure future R&D and manufacturing commitments. Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
• Negative Sentiment: Another potential overhang is Lilly beginning to deny some 340B discounts, which could increase policy and pricing friction with healthcare providers and public programs. Eli Lilly begins denying 340B discounts

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,098.78 on Friday. The business has a 50 day moving average price of $1,013.17 and a 200 day moving average price of $1,016.84. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The company has a market cap of $1.03 trillion, a price-to-earnings ratio of 39.03, a PEG ratio of 1.22 and a beta of 0.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the firm posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday. Barclays increased their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Guggenheim reissued a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Finally, Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,227.74.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.